Objective: To investigate the effect of bevacizumab in the treatment of children with optic pathway glioma (OPG).
Methods: A retrospective analysis was performed for the clinical data of 30 children with OPG who underwent chemotherapy. According to whether bevacizumab was used, they were divided into conventional chemotherapy (carboplatin, vincristine and etoposide) group with 12 children and combined chemotherapy (bevacizumab, carboplatin, vincristine and etoposide) group with 18 children. The children were followed up to 6 months after chemotherapy, and the two groups were compared in terms of visual acuity and tumor size before and after chemotherapy and adverse reactions during chemotherapy.
Results: The combined chemotherapy group had a significantly higher proportion of children achieving tumor regression than the conventional chemotherapy group (P<0.05), while there were no significant differences between the two groups in the proportion of children with improved visual acuity or adverse reactions (P>0.05). No chemotherapy-related death was observed in either group.
Conclusions: Bevacizumab combined with conventional chemotherapy can effectively reduce tumor size. Compared with conventional chemotherapy, such combination does not increase adverse reactions and can thus become a new direction for the treatment of OPG in children.
目的: 分析贝伐珠单抗治疗儿童视路胶质瘤（OPG）的效果，为儿童OPG的治疗探索新方向。
方法: 回顾性分析术后化疗的OPG患儿30例，根据是否加用贝伐珠单抗分为传统化疗组（卡铂、长春新碱、依托泊苷，n=12）和联合化疗组（贝伐珠单抗、卡铂、长春新碱、依托泊苷，n=18）。随访至化疗后6个月，比较两组患儿化疗前后的视力、肿瘤大小及化疗期间出现的不良反应。
结果: 联合化疗组肿瘤缩小患儿比例高于传统化疗组（P < 0.05）。两组视力好转率、不良反应发生率差异无统计学意义（P > 0.05）。两组均无化疗相关的死亡病例。
结论: 贝伐珠单抗联合传统化疗可有效使肿瘤体积缩小，且与传统化疗相比，化疗的不良反应并不增加，可作为儿童OPG新的治疗方向。